Transitional Cell Carcinoma Market Scope
Transitional cell carcinoma or urothelial carcinoma is a malignant neoplasm occurring from urothelium. The disease is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) is the most common tumor of the entire urinary system and TCC is the most common primary neoplasm of the urinary bladder. TCC accounted for approximately 90% of all urinary cancer cases.
The Transitional Cell Carcinoma market study is segmented, by Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers and Pharmacies) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Transitional Cell Carcinoma market throughout the predicted period.
F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. (United States), AstraZeneca (United Kingdom), Pfizer Inc. (United States), Genentech (United States), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Dendreon (United States) and Sanofi Aventis (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bristol-Myers Squibb Company (United States) and Eisai (Japan).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Transitional Cell Carcinoma market by Type, Application and Region.
On the basis of geography, the market of Transitional Cell Carcinoma has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In jan 2020, Roche announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.
On 12th April 2019, The U.S. Food and Drug Administration has granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Patients should be selected for therapy with Balversa using an FDA-approved companion diagnostic device.
- Introduction of New Diagnosis Tools
- Rise in the Incidence of Urothelial Cancer
- Increasing Healthcare Expenditure
- Clinical Trial Review of the Therapeutics to Treat Transitional Cell Carcinoma
- High Adoption of Advanced Healthcare Services & Technology in Developing Nations
- High Cost of Nonseminomatous Testicular Cancer Treatment
- Lack of Skilled Professionals
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Transitional Cell Carcinoma Drug Companies, Suppliers and Distributors of Drugs, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and Hospitals and Healthcare Institutions
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase